Physician
Sterling Pathology Medical Corporation
Sterling Pathology Medical Corporation was paid $609K by Medicaid between Jan 2018 and Oct 2024, across 8 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 36% of everything it billed.
33Billing provider infoSTERLING PATHOLOGY MEDICAL CORPORATION
SEAL BEACH, CA 90740
SEAL BEACH, CA 90740
33aNPI1255324018assigned 08/26/2005
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$609K
24GClaims20,442
24DCodes billed8
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in California
Rank by total paid#50 of 222
Median peer was paid$42K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,813 | $86K | |
| 2019 | 2,387 | $76K | |
| 2020 | 4,932 | $174K | |
| 2021 | 4,280 | $164K | |
| 2022 | 2,185 | $39K | |
| 2023 | 2,699 | $41K | |
| 2024incomplete | 2,146 | $28K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 36% | 7,187 | 6,962 | $217K |
| 88313 | 35% | 7,184 | 6,912 | $210K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 18% | 1,746 | 1,547 | $111K |
| 88312 | 9.8% | 3,591 | 3,565 | $60K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 273 | 225 | $4K |
| 88342 | <1% | 217 | 208 | $4K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 59 | 55 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 185 | 160 | $1K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, CHANGGAO (CEO)